Is ApoB a better monitoring choice than ferritin on oral semaglutide?

Setup, so nobody has to ask: ApoB · ferritin · oral semaglutide.

I have used one of these for a while and I am considering switching, which requires a reason.

What I care about is reproducibility, because a result I cannot repeat is not useful to me.

Which axes does this decision turn on?

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Relative to absolute, worked

The last two rows describe the same finding. Only one of them is used in headlines.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Decide the action for each result before you order the test.

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Research-use compounds are not approved for human use, and no panel makes that safer.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 15 Apr 2026 by Dr_Colm_Fitzhenry — corrected a unit error in the worked example

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

edited 16 Mar 2026 by Dr_Rosalind_Achebe — added a caveat about sampling